{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:48:50Z","timestamp":1784630930803,"version":"3.55.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T00:00:00Z","timestamp":1391472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1038\/nrclinonc.2014.3","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T10:21:25Z","timestamp":1391509285000},"page":"157-166","source":"Crossref","is-referenced-by-count":55,"title":["Bilateral breast cancers"],"prefix":"10.1038","volume":"11","author":[{"given":"Steven A.","family":"Narod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,4]]},"reference":[{"key":"BFnrclinonc20143_CR1","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1586\/era.11.100","volume":"11","author":"M Barry","year":"2011","unstructured":"Barry, M. & Sacchini, V. When is contralateral mastectomy warranted in unilateral breast cancer? Expert Rev. Anticancer Ther. 11, 1209\u20131214 (2011).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"BFnrclinonc20143_CR2","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1016\/S1470-2045(13)70047-0","volume":"14","author":"JA Murphy","year":"2013","unstructured":"Murphy, J. A., Milner, T. D. & O'Donoghue, J. M. Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol. 14, e262\u2013e269 (2013).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc20143_CR3","volume-title":"Why more women are choosing double mastectomies","author":"A Gilbert","year":"2013","unstructured":"Gilbert, A. Why more women are choosing double mastectomies [online] , (2013)."},{"key":"BFnrclinonc20143_CR4","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1200\/JCO.2007.12.3141","volume":"25","author":"TM Tuttle","year":"2007","unstructured":"Tuttle, T. M., Habermann, E. B., Grund, E. H., Morris, T. J. & Virnig, B. A. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J. Clin. Oncol. 25, 5203\u20135209 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc20143_CR5","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1200\/JCO.2010.29.4041","volume":"29","author":"TA King","year":"2011","unstructured":"King, T. A. et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J. Clin. Oncol. 29, 2158\u20132164 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc20143_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.7326\/0003-4819-159-6-201309170-00003","volume":"159","author":"SM Rosenberg","year":"2013","unstructured":"Rosenberg, S. M. et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann. Intern. Med. 159, 373\u2013381 (2013).","journal-title":"Ann. Intern. Med."},{"key":"BFnrclinonc20143_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/annonc\/mdp470","volume":"21","author":"B Banelli","year":"2010","unstructured":"Banelli, B. et al. Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer. Ann. Oncol. 21, 1237\u20131242 (2010).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc20143_CR8","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","volume":"139","author":"MY Kim","year":"2009","unstructured":"Kim, M. Y. et al. Tumor self-seeding by circulating cancer cells. Cell 139, 1315\u20131326 (2009).","journal-title":"Cell"},{"key":"BFnrclinonc20143_CR9","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2006.10.5056","volume":"25","author":"M Hartman","year":"2007","unstructured":"Hartman, M. et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J. Clin. Oncol. 25, 4210\u20134216 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc20143_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-007-9709-2","volume":"110","author":"M Schaapveld","year":"2008","unstructured":"Schaapveld, M. et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res. Treat. 110, 189\u2013197 (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc20143_CR11","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/cncr.20452","volume":"101","author":"M Intra","year":"2004","unstructured":"Intra, M. et al. Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Cancer 101, 905\u2013912 (2004).","journal-title":"Cancer"},{"key":"BFnrclinonc20143_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/cncr.25587","volume":"117","author":"D Huo","year":"2011","unstructured":"Huo, D., Melkonian, S., Rathouz, P. J., Khramtsov, A. & Olopade, O. I. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer 117, 907\u2013915 (2011).","journal-title":"Cancer"},{"key":"BFnrclinonc20143_CR13","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1200\/JCO.2008.21.5756","volume":"27","author":"ME Brennan","year":"2009","unstructured":"Brennan, M. E. et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J. Clin. Oncol. 27, 5640\u20135649 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc20143_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/SLA.0b013e3182125b26","volume":"254","author":"TA King","year":"2011","unstructured":"King, T. A. et al. Occult malignancy in patients undergoing contralateral prophylactic mastectomy. Ann. Surg. 254, 2\u20137 (2011).","journal-title":"Ann. Surg."},{"key":"BFnrclinonc20143_CR15","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1245\/s10434-009-0362-3","volume":"16","author":"ME Sorbero","year":"2009","unstructured":"Sorbero, M. E., Dick, A. W., Beckjord, E. B. & Ahrendt, G. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann. Surg. Oncol. 16, 1597\u20131605 (2009).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrclinonc20143_CR16","first-page":"855","volume":"8","author":"Y Chen","year":"1999","unstructured":"Chen, Y., Thompson, W., Semenciw, R. & Mao, Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol. Biomarkers Prev. 8, 855\u2013861 (1999).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"BFnrclinonc20143_CR17","unstructured":"National Comprehensive Cancer Network (NCCN) in Breast Cancer NCCN Practice Guidelines in Oncology (ver. 2.2011) binv-16 (NCCN, 2011)."},{"key":"BFnrclinonc20143_CR18","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/annonc\/mdp037","volume":"20","author":"N Houssami","year":"2009","unstructured":"Houssami, N., Ciatto, S., Martinelli, F., Bonardi, R. & Duffy, S. W. Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann. Oncol. 20, 1505\u20131510 (2009).","journal-title":"Ann. Oncol."},{"key":"BFnrclinonc20143_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1200\/JCO.2006.09.5448","volume":"26","author":"LJ Solin","year":"2008","unstructured":"Solin, L. J., Orel, S. G., Hwang, W. T., Harris, E. E. & Schnall, M. D. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J. Clin. Oncol. 26, 386\u2013391 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc20143_CR20","unstructured":"Cancer Incidence in Five Continents Volume VIII (eds Parkin, D. M. et al.) (International Agency for Research on Cancer, 2002)."},{"key":"BFnrclinonc20143_CR21","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/jnci\/83.18.1299","volume":"83","author":"LE Rutqvist","year":"1991","unstructured":"Rutqvist, L. E. et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J. Natl Cancer Inst. 83, 1299\u20131306 (1991).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc20143_CR22","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/1097-0215(20001215)88:6<998::AID-IJC25>3.0.CO;2-0","volume":"88","author":"P Vaittinen","year":"2000","unstructured":"Vaittinen, P. & Hemminki, K. Risk factors and age-incidence relationships for contralateral breast cancer. Int. J. Cancer 88, 998\u20131002 (2000).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc20143_CR23","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/jnci\/djp181","volume":"101","author":"AW Kurian","year":"2009","unstructured":"Kurian, A. W. et al. Second primary breast cancer occurrence according to hormone receptor status. J. Natl Cancer Inst. 101, 1058\u20131065 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc20143_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccr.2007.01.010","volume":"11","author":"T Walsh","year":"2007","unstructured":"Walsh, T. & King, M. C. Ten genes for inherited breast cancer. Cancer Cell 11, 103\u2013105 (2007).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc20143_CR25","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/bjc.2011.120","volume":"104","author":"K Metcalfe","year":"2011","unstructured":"Metcalfe, K. et al. Predictors of contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br. J. Cancer 104, 1384\u20131392 (2011).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc20143_CR26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat, N. et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J. Natl Cancer Inst. 105, 812\u2013822 (2013).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc20143_CR27","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1200\/JCO.2009.24.2495","volume":"28","author":"KE Malone","year":"2010","unstructured":"Malone, K. E. et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J. Clin. Oncol. 28, 2404\u20132410 (2010).","journal-title":"BRCA2. J. Clin. Oncol."},{"key":"BFnrclinonc20143_CR28","unstructured":"Narod, S. A. et al. A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers Curr. Oncol. (in press)."},{"key":"BFnrclinonc20143_CR29","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","volume":"27","author":"MK Graeser","year":"2009","unstructured":"Graeser, M. K. et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 27, 5887\u20135892 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc20143_CR30","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/ijc.21536","volume":"118","author":"J Gronwald","year":"2006","unstructured":"Gronwald, J. et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int. J. Cancer 118, 2281\u20132284 (2006).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc20143_CR31","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","volume":"31","author":"KA Phillips","year":"2013","unstructured":"Phillips, K. A. et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 31, 3091\u20133099 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc20143_CR32","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek, S. M. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304, 967\u2013975 (2010).","journal-title":"JAMA"},{"key":"BFnrclinonc20143_CR33","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10549-010-0769-3","volume":"123","author":"KW Reding","year":"2010","unstructured":"Reding, K. W. et al. Adjuvant systemic therapy for breast cancer in BRCA1\/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res. Treat. 123, 491\u2013498 (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc20143_CR34","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1002\/ijc.23340","volume":"122","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe, K. A. et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer 122, 2017\u20132022 (2008).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc20143_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1023\/A:1015269620265","volume":"73","author":"LN Lodder","year":"2002","unstructured":"Lodder, L. N. et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res. Treat. 73, 97\u2013112 (2002).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc20143_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-013-2583-1","volume":"140","author":"DG Evans","year":"2013","unstructured":"Evans, D. G. et al. Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer. Breast Cancer Res. Treat. 140, 135\u2013142 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc20143_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/cge.12149","volume":"85","author":"Y Laitman","year":"2014","unstructured":"Laitman, Y. et al. Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers. Clin. Genet. 85, 68\u201371 (2014).","journal-title":"Clin. Genet."},{"key":"BFnrclinonc20143_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/cge.12216","volume":"85","author":"CF Singer","year":"2014","unstructured":"Singer, C. F. et al. Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria. Clin. Genet. 85, 72\u201375 (2014).","journal-title":"Clin. Genet."},{"key":"BFnrclinonc20143_CR39","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1158\/0008-5472.CAN-07-5187","volume":"68","author":"S Zhang","year":"2008","unstructured":"Zhang, S. et al. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. Cancer Res. 68, 2154\u20132157 (2008).","journal-title":"Cancer Res."},{"key":"BFnrclinonc20143_CR40","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/sj.bjc.6604228","volume":"98","author":"L Mellemkjaer","year":"2008","unstructured":"Mellemkjaer, L. et al. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study. Br. J. Cancer 98, 728\u2013733 (2008).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc20143_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1023\/B:BREA.0000010697.49896.03","volume":"83","author":"A Broeks","year":"2004","unstructured":"Broeks, A. et al. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res. Treat. 83, 91\u201393 (2004).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc20143_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0004.2010.01402.x","volume":"78","author":"SA Narod","year":"2010","unstructured":"Narod, S. A. Testing for CHEK2 in the cancer genetics clinic: ready for prime time? Clin. Genet. 78, 1\u20137 (2010).","journal-title":"Clin. Genet."},{"key":"BFnrclinonc20143_CR43","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2217\/fon.09.29","volume":"5","author":"M Ghoussaini","year":"2009","unstructured":"Ghoussaini, M. & Pharoah, P. D. Polygenic susceptibility to breast cancer: current state-of-the-art. Future Oncol. 5, 689\u2013701 (2009).","journal-title":"Future Oncol."},{"key":"BFnrclinonc20143_CR44","doi-asserted-by":"publisher","first-page":"R114","DOI":"10.1186\/bcr3057","volume":"13","author":"SN Teraoka","year":"2011","unstructured":"Teraoka, S. N. et al. Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study. Breast Cancer Res. 13, R114 (2011).","journal-title":"Breast Cancer Res."},{"key":"BFnrclinonc20143_CR45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/oxfordjournals.aje.a114971","volume":"128","author":"PL Horn","year":"1998","unstructured":"Horn, P. L. & Thompson, W. D. Risk of contralateral breast cancer: associations with factors related to initial breast cancer. Am. J. Epidemiol. 128, 309\u2013323 (1998).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrclinonc20143_CR46","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2012.43.2013","volume":"31","author":"AS Reiner","year":"2013","unstructured":"Reiner, A. S. et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. J. Clin. Oncol. 31, 433\u2013439 (2013).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc20143_CR47","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10552-010-9510-0","volume":"21","author":"JN Poynter","year":"2010","unstructured":"Poynter, J. N. et al. Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study. Cancer Causes Control 21, 839\u2013846 (2010).","journal-title":"Cancer Causes Control"},{"key":"BFnrclinonc20143_CR48","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1158\/1055-9965.EPI-06-1003","volume":"16","author":"JA Largent","year":"2007","unstructured":"Largent, J. A. et al. Reproductive history and risk of second primary breast cancer: the WECARE study. Cancer Epidemiol. Biomarkers Prev. 16, 906\u2013911 (2007).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"BFnrclinonc20143_CR49","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/aje\/kwn422","volume":"169","author":"JA Knight","year":"2009","unstructured":"Knight, J. A. et al. Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: The Women's Environmental Cancer and Radiation Epidemiology Study. Am. J. Epidemiol. 169, 962\u2013968 (2009).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrclinonc20143_CR50","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1200\/JCO.2007.14.3081","volume":"26","author":"JC Figueiredo","year":"2008","unstructured":"Figueiredo, J. C. et al. Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group. J. Clin. Oncol. 26, 1411\u20131418 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc20143_CR51","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10549-011-1743-4","volume":"131","author":"JD Brooks","year":"2012","unstructured":"Brooks, J. D. et al. Body mass index and risk of second primary breast cancer: the WECARE Study. Breast Cancer Res. Treat. 131, 571\u2013580 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc20143_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/bcr2942","volume":"13","author":"NF Boyd","year":"2011","unstructured":"Boyd, N. F., Martin, L. J., Yaffe, M. J. & Minkin, S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res. 13, 223 (2011).","journal-title":"Breast Cancer Res."},{"key":"BFnrclinonc20143_CR53","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1002\/cncr.24638","volume":"115","author":"T Cil","year":"2009","unstructured":"Cil, T. et al. Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery. Cancer 115, 5780\u20135787 (2009).","journal-title":"Cancer"},{"key":"BFnrclinonc20143_CR54","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1186\/bcr3451","volume":"15","author":"ME Sandberg","year":"2013","unstructured":"Sandberg, M. E. et al. Change of mammographic density predicts the risk of contralateral breast cancer: a case\u2013control study. Breast Cancer Res. 15, R57 (2013).","journal-title":"Breast Cancer Res."},{"key":"BFnrclinonc20143_CR55","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","volume":"3","author":"VG Vogel","year":"2010","unstructured":"Vogel, V. G. et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev. Res. (Phila.) 3, 696\u2013706 (2010).","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"BFnrclinonc20143_CR56","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10549-007-9698-1","volume":"105","author":"PE Goss","year":"2007","unstructured":"Goss, P. E. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Res. Treat. 105, 45\u201353 (2007).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc20143_CR57","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.ejca.2009.05.022","volume":"45","author":"S Alkner","year":"2009","unstructured":"Alkner, S. et al. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: results from a controlled randomised trial. Eur. J. Cancer 45, 2496\u20132502 (2009).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc20143_CR58","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687\u20131717 (2005).","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"BFnrclinonc20143_CR59","doi-asserted-by":"publisher","first-page":"R149","DOI":"10.1186\/bcr767","volume":"6","author":"G Arpino","year":"2004","unstructured":"Arpino, G., Bardou, V. J., Clark, G. M. & Elledge, R. M. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 6, R149\u2013R156 (2004).","journal-title":"Breast Cancer Res."},{"key":"BFnrclinonc20143_CR60","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10549-012-2183-5","volume":"135","author":"BS Saltzman","year":"2012","unstructured":"Saltzman, B. S., Malone, K. E., McDougall, J. A., Daling, J. R. & Li, C. I. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Res. Treat. 135, 849\u2013855 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc20143_CR61","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnci\/djh097","volume":"96","author":"SM Swain","year":"2004","unstructured":"Swain, S. M. et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J. Natl Cancer Inst. 96, 516\u2013523 (2004).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc20143_CR62","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1200\/JCO.2005.04.076","volume":"23","author":"G Arpino","year":"2005","unstructured":"Arpino, G., Weiss, H. L., Clark, G. M., Hilsenbeck, S. G. & Osborne, C. K. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J. Clin. Oncol. 23, 4687\u20134694 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc20143_CR63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1023\/A:1014958514851","volume":"72","author":"M Safal","year":"2002","unstructured":"Safal, M. et al. Bilateral synchronous breast cancer and HER-2\/neu overexpression. Breast Cancer Res. Treat. 72, 195\u2013201 (2002).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc20143_CR64","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1055-9965.EPI-10-1016","volume":"20","author":"L Bessonova","year":"2011","unstructured":"Bessonova, L., Taylor, T. H., Mehta, R. S., Zell, J. A. & Anton-Culver, H. Risk of a second breast cancer associated with hormone-receptor and HER2\/neu status of the first breast cancer. Cancer Epidemiol. Biomarkers Prev. 20, 389\u2013396 (2011).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"BFnrclinonc20143_CR65","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1075-122X.2005.21579.x","volume":"11","author":"A Stark","year":"2005","unstructured":"Stark, A., Lu, M., Mackowiak, P. & Linden, M. Concordance of the hormone receptors and correlation of HER-2\/neu overexpression of the metachronous cancers of contralateral breasts. Breast J. 11, 183\u2013187 (2005).","journal-title":"Breast J."},{"key":"BFnrclinonc20143_CR66","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cancergencyto.2010.09.012","volume":"204","author":"HG Russnes","year":"2011","unstructured":"Russnes, H. G. et al. Paired distribution of molecular subtypes in bilateral breast carcinomas. Cancer Genet. 204, 96\u2013102 (2011).","journal-title":"Cancer Genet."},{"key":"BFnrclinonc20143_CR67","first-page":"825","volume":"34","author":"D Coradini","year":"1998","unstructured":"Coradini, D. et al. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? J. Cancer 34, 825\u2013830 (1998).","journal-title":"J. Cancer"},{"key":"BFnrclinonc20143_CR68","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1023\/B:BREA.0000025421.00599.b7","volume":"85","author":"J Kollias","year":"2004","unstructured":"Kollias, J. et al. Phenotypic similarities in bilateral breast cancer. Breast Cancer Res. Treat. 85, 255\u2013261 (2004).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc20143_CR69","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1158\/1055-9965.EPI-05-0070","volume":"14","author":"JN Weitzel","year":"2005","unstructured":"Weitzel, J. N. et al. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol. Biomarkers Prev. 14, 1534\u20131538 (2005).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"BFnrclinonc20143_CR70","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cancergencyto.2008.03.005","volume":"184","author":"EN Suspitsin","year":"2008","unstructured":"Suspitsin, E. N. et al. TP53 mutations in synchronous and metachronous bilateral breast carcinomas. Cancer Genet. Cytogenet. 184, 119\u2013121 (2008).","journal-title":"Cancer Genet. Cytogenet."},{"key":"BFnrclinonc20143_CR71","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ijc.22265","volume":"120","author":"EN Suspitsin","year":"2007","unstructured":"Suspitsin, E. N. et al. Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: possible role of host factors and survival bias. Int. J. Cancer 120, 297\u2013302 (2007).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc20143_CR72","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nrclinonc.2012.102","volume":"9","author":"SA Narod","year":"2012","unstructured":"Narod, S. A. Breast cancer in young women. Nat. Rev. Clin. Oncol. 9, 460\u2013470 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrclinonc20143_CR73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3747\/co.19.1003","volume":"19","author":"SA Narod","year":"2012","unstructured":"Narod, S. A. A model for breast cancer risk based on stem-cell theory. Curr. Oncol. 19, 9\u201311 (2012).","journal-title":"Curr. Oncol."},{"key":"BFnrclinonc20143_CR74","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.tem.2004.05.011","volume":"15","author":"G Dontu","year":"2004","unstructured":"Dontu, G., El-Ashry, D. & Wicha, M. S. Breast cancer, stem\/progenitor cells and the estrogen receptor. Trends Endocrinol. Metab. 15, 193\u2013197 (2004).","journal-title":"Trends Endocrinol. Metab."},{"key":"BFnrclinonc20143_CR75","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nature11725","volume":"493","author":"E Ruark","year":"2013","unstructured":"Ruark, E. et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 493, 406\u2013410 (2013).","journal-title":"Nature"},{"key":"BFnrclinonc20143_CR76","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.celrep.2012.12.020","volume":"3","author":"B Pal","year":"2013","unstructured":"Pal, B. et al. Global changes in the mammary epigenome are induced by hormonal cues and coordinated by Ezh2. Cell Rep. 3, 411\u2013426 (2013).","journal-title":"Cell Rep."},{"key":"BFnrclinonc20143_CR77","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10549-011-1479-1","volume":"128","author":"SA Narod","year":"2011","unstructured":"Narod, S. A. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res. Treat. 128, 581\u2013583 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc20143_CR78","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1002\/cncr.27574","volume":"118","author":"AM Brewster","year":"2012","unstructured":"Brewster, A. M. et al. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer 118, 5637\u20135643 (2012).","journal-title":"Cancer"},{"key":"BFnrclinonc20143_CR79","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1200\/JCO.2005.10.080","volume":"23","author":"LJ Herrinton","year":"2005","unstructured":"Herrinton, L. J. et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J. Clin. Oncol. 23, 4275\u20134286 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc20143_CR80","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/jnci\/djq018","volume":"102","author":"I Bedrosian","year":"2010","unstructured":"Bedrosian, I., Hu, C. Y. & Chang, G. J. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J. Natl Cancer Inst. 102, 401\u2013409 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc20143_CR81","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/sim.1668","volume":"23","author":"J Tyrer","year":"2004","unstructured":"Tyrer, J., Duffy, S. W. & Cuzick, J. A breast cancer prediction model incorporating familial and personal risk factors. Stat. Med. 23, 1111\u20131130 (2004).","journal-title":"Stat. Med."},{"key":"BFnrclinonc20143_CR82","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/sj.bjc.6605283","volume":"101","author":"HE Campbell","year":"2009","unstructured":"Campbell, H. E., Taylor, M. A., Harris, A. L. & Gray, A. M. An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br. J. Cancer 101, 1074\u20131084 (2009).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc20143_CR83","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1186\/bcr2464","volume":"12","author":"GC Wishart","year":"2010","unstructured":"Wishart, G. C. et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 12, R1 (2010).","journal-title":"Breast Cancer Res."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2014.3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2014.3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2014.3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:26:36Z","timestamp":1684466796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2014.3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,4]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["BFnrclinonc20143"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2014.3","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,4]]}}}